보고서 요약(국문)

시장 개요
전 세계 폰다파리눅스 시장 규모는 2022년 XX백만 달러였으며, 2030년까지 XX백만 달러에 이를 것으로 예상됩니다. 예측 기간(2023-2030년) 동안 연평균 성장률(CAGR)은 XX%입니다.
폰다파리눅스는 다리, 폐 및 기타 신체 부위의 혈전 예방 및 치료에 사용되는 합성 항응고제 또는 혈액 희석제입니다. 혈액 내 트롬빈이라는 특정 효소의 활동을 억제하여 혈전 형성을 방지하는 방식으로 작용합니다. 폰다파리눅스는 피하 주사로 투여되며, 혈전 위험을 줄이기 위해 다른 약물과 병용하여 사용되는 경우가 많습니다.
시장 동향
기술 발전, 심혈관 질환 부담 증가, 고령 인구 증가, 연구 개발 활동 및 무릎 및 고관절 수술 건수 증가 등이 전 세계 폰다파리눅스 시장 성장을 견인하고 있습니다.

심혈관 질환 부담 증가가 시장 성장을 견인하고 있습니다.
허혈성 심장 질환과 뇌졸중은 전 세계적으로 사망과 장애의 주요 원인입니다. 심혈관 질환(CVD)은 장애의 또 다른 중요한 원인입니다. 미국 심장학회지(Journal of American College of Cardiology)에 발표된 논문에 따르면, 2022년에는 187만 명(95% CI: 144만~234만 명)이 심혈관 질환으로 사망했고, 전체 사망자 347만 명(95% CI: 293만~400만 명)이 신장 기능 저하로 인한 사망이었습니다. 거의 모든 비고소득 국가에서 심혈관 질환 부담이 지속적으로 증가하고 있으며, 더욱 우려스러운 것은 고소득 국가에서 감소세를 보였던 여러 지역에서 연령 표준화 심혈관 질환 발생률이 다시 상승하기 시작했다는 점입니다.
또한, 건강하지 못한 식습관, 운동 부족, 담배 사용, 알코올 남용은 심장 질환과 뇌졸중의 주요 행동 위험 요인입니다. 개인은 행동 위험 요인으로 인해 고혈압, 고혈당, 고지혈증뿐만 아니라 과체중 및 비만을 경험할 수 있습니다.
또한, 2022년 2월 중국 합동조달사무소(JPO)는 폰다파리눅스 7차 대량 구매(VBP) 관련 의약품 정보 수집 공고를 발표했는데, 이는 중국의 국가 의약품 대량 구매를 촉진할 것입니다.
폰다파리눅스와 관련된 부작용은 시장 성장을 저해할 수 있습니다.
폰다파리눅스는 혈전 예방 및 치료에 사용되는 항응고제입니다. 폰다파리눅스의 일반적인 부작용으로는 출혈, 멍, 피부의 붉거나 보라색 반점, 위 또는 복부 통증 등이 있습니다. 그 외 가능한 부작용으로는 주사 부위의 혈종, 통증, 부기 및 발적, 알레르기 반응 등이 있습니다.
코로나19 영향 분석
코로나19 팬데믹은 폰다파리눅스 시장에 긍정적인 영향을 미쳤습니다. 세계보건기구(WHO)는 코로나19 환자의 정맥혈전색전증 예방을 위해 헤파린을 이용한 약물 예방 요법을 권장합니다. 의료진의 개인 보호 장비 사용 및 노출을 줄이기 위해 저분자량 헤파린 또는 폰다파리눅스의 1일 1회 투여 요법이 비분획 헤파린보다 선호됩니다.
코로나19 팬데믹은 폰다파리눅스 시장에 영향을 미쳤을 가능성이 높습니다. 이 약물은 혈전 예방에 사용되며, 코로나19 환자와 같이 중증이거나 입원한 환자에게 자주 투여됩니다. 따라서 팬데믹 기간 동안 폰다파리눅스에 대한 수요가 증가했을 수 있습니다.
세그먼트 분석
심혈관 부문은 예측 기간(2023-2030년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
심혈관 부문은 가장 높은 시장 점유율을 차지합니다. 폰다파리눅스는 다리, 폐 및 기타 장기의 정맥 혈전을 예방하고 치료하는 데 사용되는 합성 항응고제입니다. 이는 혈액 응고 인자인 트롬빈의 생성을 억제하는 인자 Xa 억제제로, 인자 Xa에 결합하여 그 작용을 저해합니다. 따라서 고관절 또는 무릎 관절 치환술과 같은 특정 유형의 수술 후 발생할 수 있는 심각한 합병증인 심부정맥혈전증(DVT) 및 폐색전증(PE)의 위험을 낮춥니다.
또한 폰다파리눅스는 불안정형 협심증 및 비ST분절 상승 심근경색(NSTEMI)과 같은 급성 관상동맥 증후군(ACS) 환자의 치료에도 사용됩니다. 일반적으로 1일 1회 피하 주사로 투여하며, 신장 기능 장애 환자에게도 용량 조절이 필요하지 않아 선호됩니다.

폰다파리눅스는 매우 효과적인 항응고제로, 에녹사파린이나 와파린과 같은 다른 항응고제만큼 안전하고 효과적입니다. 하지만 다른 항응고제보다 반감기가 길어 체내에 더 오래 머무르며 출혈 위험이 낮습니다. 또한 다른 약물과의 상호작용 가능성이 낮아 여러 약물을 복용하는 환자에게 매력적인 선택지입니다.
지역 분석
아시아 태평양 지역은 전 세계 폰다파리눅스 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
아시아 태평양 지역은 폰다파리눅스 시장을 주도하고 있으며, 예측 기간 동안에도 이러한 추세가 지속될 것으로 예상됩니다. 심장 질환 유병률 증가와 아시아 태평양 지역의 활발한 시장 참여가 시장 성장을 견인하고 있습니다.
2022년 세계 심장학 저널(World Journal of Cardiology)에 발표된 논문에 따르면, 급성 관상동맥 증후군(ACS)은 전 세계적으로 주요 사망 원인 중 하나입니다. 다른 국가들과 비교했을 때, 남아시아인들은 더 젊은 나이에 심근경색(MI)을 경험하는 비율이 높습니다(평균 연령 53세 vs. 평균 연령 58.8세). 인도 인구의 경우, 급성 관상동맥 증후군(ACS) 발병 연령 또한 서구보다 10년 정도 빠릅니다. 더욱이, 인도는 전 세계에서 ACS 발병률이 가장 높은 국가로, 백인 미국인의 3~4배, 중국인의 6배, 일본인의 20배에 달합니다. ACS는 인도에서 매년 300만 명의 사망자를 발생시키며, 전체 사망 원인의 25%를 차지합니다. 항응고 치료는 ACS 관리의 핵심입니다. 아시아 태평양 지역에서 심장 질환 부담이 증가함에 따라 폰다파리눅스 시장이 성장하고 있습니다.

경쟁 환경
폰다파리눅스 시장은 국내외 기업들이 경쟁하는 비교적 안정적인 시장입니다. 폰다파리눅스 시장 성장에 기여하는 주요 기업으로는 Dr. Reddy's Laboratories, Inc., GlaxoSmithKline Plc, Mylan N.V., Pfizer, Inc., Bayer Healthcare AG, Boehringer Ingelheim, Sanofi S.A., Abbott, Aspen Holdings, Bristol-Myers Squibb Company 등이 있습니다. 주요 기업들은 신제품 출시, 인수, 협력 등 다양한 성장 전략을 통해 전 세계 폰다파리눅스 시장의 성장을 견인하고 있습니다.
Dr. Reddy's Laboratories, Inc.
개요:
Dr. Reddy's Laboratories, Inc.는 1984년에 설립되었으며 인도에 본사를 두고 있습니다. 이 회사는 원료의약품(API), 제네릭 의약품, 브랜드 제네릭 의약품, 바이오시밀러, 일반의약품 등 핵심 사업 분야에 걸쳐 전 세계적으로 제품과 서비스를 제공합니다.

제품 포트폴리오:
폰다파리눅스 나트륨 주사제: 고관절 치환술, 무릎 수술 등 하지 정형외과 수술을 받은 환자 또는 정맥혈전색전증(VTE) 예방을 위해 수술 후 최대 한 달 동안 사용됩니다.
글로벌 폰다파리눅스 시장 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량으로 구성되어 있습니다.

보고서 요약(영어 원문)

Market Overview
The global fondaparinux market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period (2023-2030).
Fondaparinux is a synthetic anticoagulant, or blood thinner, used to prevent and treat blood clots in the legs, lungs, and other body parts. It works by hindering the activity of a specific enzyme in the blood called thrombin, which helps to prevent the formation of clots. Fondaparinux is administered by injection under the skin and is often used in combination with other medications to reduce the risk of blood clots.
Market Dynamics
Technological advancements, the growing burden of cardiovascular disease, the increasing geriatric population, research and development activities and rising surgical procedures of knee & hip cases drive the global fondaparinux market growth.
Growing burden of cardiovascular disease drives the market growth
Ischemic heart disease and stroke are the primary causes of mortality and disability worldwide. Cardiovascular diseases (CVDs) are another important cause of disability. As per the article published in the Journal of American College of Cardiology, in 2022, 1.87 million (95% CI: 1.44-2.34 million) cardiovascular deaths and 3.47 million (95% CI: 2.93-4.00 million) deaths overall were attributable to reduced kidney function. Nearly all non-high-income nations continue to experience an increase in the burden of CVD, and frighteningly, the age-standardized rate of CVD has started to rise in several areas where it had been dropping in high-income countries.
In addition, unhealthy eating, inactivity, usage of tobacco products, and abusing alcohol are the main behavioral risk factors for heart disease and stroke. Individuals may experience elevated blood pressure, elevated blood glucose, elevated blood lipids, as well as overweight and obesity as a result of behavioral risk factors.
In addition, in February 2022, the Joint Procurement Office (JPO) of China issued a notice to collect drug information related to the seventh batch of volume-based procurement (VBP) of fondaparinux, which will boost China’s national bulk buying of drugs.
The side effects associated with fondaparinux will hamper the growth of the market
However, Fondaparinux is an anticoagulant medication used to prevent and treat blood clots. Some common side effects of fondaparinux include bleeding, bruising, red or purple spots on the skin, and stomach or abdominal pain. Other possible side effects include hematoma, pain, swelling and redness at the injection site, and allergic reactions.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a positive impact on the fondaparinux market. The World Health Organization recommends using pharmacological prophylaxis with heparin for venous thromboembolism prevention in COVID-19 patients. The once-daily dosing regimen of low-molecular-weight heparins or fondaparinux should be preferred over unfractionated heparin to reduce personal protective equipment use and exposure of healthcare workers.
The COVID-19 pandemic has likely had an impact on the market for fondaparinux. This medication is used to prevent blood clots and is often given to patients who are critically ill or hospitalized, such as those with COVID-19. As a result, there may have been an increased demand for fondaparinux during the pandemic.
Segment Analysis
The cardiovascular segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
The cardiovascular segment accounts for the highest market share. Fondaparinux is a synthetic anticoagulant medication used to prevent and treat blood clots in the veins of the legs, lungs and other organs. It is a factor Xa inhibitor, which prevents the formation of thrombin, a clotting factor in the blood, by binding to and inhibiting factor Xa. This lowers the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), serious complications that can occur after certain types of surgery, such as hip or knee replacement.
Fondaparinux is also used in treating patients with acute coronary syndromes (ACS), such as unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI). It is usually administered in subcutaneous injection once daily, and it is preferred in patients with renal impairment because it does not require dose adjustments.
Fondaparinux is a highly effective anticoagulant and is as safe and effective as other anticoagulants such as enoxaparin and warfarin. However, it has a longer half-life than other anticoagulants, which means it stays in the body longer and has a lower risk of bleeding. It is also less likely to interact with other medications, making it an attractive option for patients taking multiple medications.
Geographical Analysis
Asia Pacific region holds the largest market share of the global Fondaparinux market
Asia Pacific dominates the market for fondaparinux and is expected to show a similar trend over the forecast period. The rising prevalence of heart disease and active regional players in the Asia Pacific region drives the market.
As per the article published in the World Journal of Cardiology in 2022, acute coronary syndrome (ACS) is one of the main causes of fatality worldwide. Compared to other countries, South Asians have a higher rate of myocardial infarction (MI) at a younger age (average age 53 vs. average age 58.8 years). In the Indian population, ACS also presents a decade earlier than the West. Furthermore, India has the greatest ACS load in the world, with a burden of 3 to 4 times that of White Americans, six times that of Chinese, and 20 times that of Japanese people. ACS is responsible for 3 million fatalities annually in India, accounting for 25% of all deaths. Anti-coagulant therapies form the cornerstone in the management of ACS. The rising burden of heart disease in the Asia Pacific region drives the market for fondaparinux.
Competitive Landscape
The fondaparinux market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Dr. Reddy's Laboratories, Inc., GlaxoSmithKline Plc, Mylan N.V., Pfizer, Inc., Bayer Healthcare AG, Boehringer Ingelheim, Sanofi S.A., Abbott, Aspen Holdings, and Bristol-Myers Squibb Company, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the fondaparinux market globally.
Dr. Reddy’s Laboratories, Inc.
Overview:
Dr. Reddy’s Laboratories, Inc was founded in 1984 and headquartered in India. The company provides products and services spread across its core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products worldwide.
Product Portfolio:
Fondaparinux Sodium Injection: It is used for patients having orthopedic procedures on their lower limbs, such as hip replacement, knee surgery, or prophylaxis against venous thromboembolic events (VTE), for up to a month following surgery.
The global fondaparinux market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

상세 목차

1. Market Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of chronic diseases
4.1.1.2. Growth in geriatric population
4.1.2. Restraints:
4.1.2.1. Side effects caused by drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Branded*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2021-2030
7.3. Generic
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Orthopedics*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2021-2030
8.3. Cardiovascular
8.4. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals and Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030.
9.3. Diagnostic Centers
9.4. Ambulatory Surgical Centers
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2021-2030, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Type Benchmarking
12. Company Profiles
12.1. Dr. Reddy’s Laboratories, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. GlaxoSmithKline Plc
12.3. Mylan N.V.
12.4. Pfizer, Inc.
12.5. Bayer Healthcare AG
12.6. Boehringer Ingelheim
12.7. Sanofi S.A.
12.8. Abbott
12.9. Aspen Holdings
12.10. Bristol-Myers Squibb Company
LIST NOT EXHAUSTIVE
13. Global Fondaparinux Market – DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

언급된 주요 기업들

Dr. Reddy’s Laboratories, Inc., GlaxoSmithKline Plc, Mylan N.V., Pfizer, Inc., Bayer Healthcare AG, Boehringer Ingelheim, Sanofi S.A., Abbott, Aspen Holdings, Bristol-Myers Squibb Company

표 목록 (Tables)

List of Tables

Table 01 Global Fondaparinux Market Value, By Type, 2023, 2027 & 2031 ($ Million)

Table 02 Global Fondaparinux Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table 03 Global Fondaparinux Market Value, By End User, 2023, 2027 & 2031 ($ Million)

Table 04 Global Fondaparinux Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 05 Global Fondaparinux Market Value, By Type, 2023, 2027 & 2031 ($ Million)

Table 06 Global Fondaparinux Market Value, By Type, 2022-2031 ($ Million)

Table 07 Global Fondaparinux Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table 08 Global Fondaparinux Market Value, By Application, 2022-2031 ($ Million)

Table 09 Global Fondaparinux Market Value, By End User, 2023, 2027 & 2031 ($ Million)

Table 10 Global Fondaparinux Market Value, By End User, 2022-2031 ($ Million)

Table 11 Global Fondaparinux Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 12 Global Fondaparinux Market Value, By Region, 2022-2031 ($ Million)

Table 13 North America Fondaparinux Market Value, By Type, 2022-2031 ($ Million)

Table 14 North America Fondaparinux Market Value, By Application, 2022-2031 ($ Million)

Table 15 North America Fondaparinux Market Value, By End User, 2022-2031 ($ Million)

Table 16 North America Fondaparinux Market Value, By Country, 2022-2031 ($ Million)

Table 17 South America Fondaparinux Market Value, By Type, 2022-2031 ($ Million)

Table 18 South America Fondaparinux Market Value, By Application, 2022-2031 ($ Million)

Table 19 South America Fondaparinux Market Value, By End User, 2022-2031 ($ Million)

Table 20 South America Fondaparinux Market Value, By Country, 2022-2031 ($ Million)

Table 21 Europe Fondaparinux Market Value, By Type, 2022-2031 ($ Million)

Table 22 Europe Fondaparinux Market Value, By Application, 2022-2031 ($ Million)

Table 23 Europe Fondaparinux Market Value, By End User, 2022-2031 ($ Million)

Table 24 Europe Fondaparinux Market Value, By Country, 2022-2031 ($ Million)

Table 25 Asia-Pacific Fondaparinux Market Value, By Type, 2022-2031 ($ Million)

Table 26 Asia-Pacific Fondaparinux Market Value, By Application, 2022-2031 ($ Million)

Table 27 Asia-Pacific Fondaparinux Market Value, By End User, 2022-2031 ($ Million)

Table 28 Asia-Pacific Fondaparinux Market Value, By Country, 2022-2031 ($ Million)

Table 29 Middle East & Africa Fondaparinux Market Value, By Type, 2022-2031 ($ Million)

Table 30 Middle East & Africa Fondaparinux Market Value, By Application, 2022-2031 ($ Million)

Table 31 Middle East & Africa Fondaparinux Market Value, By End User, 2022-2031 ($ Million)

Table 32 Dr. Reddy’s Laboratories, Inc.: Overview

Table 33 Dr. Reddy’s Laboratories, Inc.: Product Portfolio

Table 34 Dr. Reddy’s Laboratories, Inc.: Key Developments

Table 35 GlaxoSmithKline Plc: Overview

Table 36 GlaxoSmithKline Plc: Product Portfolio

Table 37 GlaxoSmithKline Plc: Key Developments

Table 38 Mylan N.V.: Overview

Table 39 Mylan N.V.: Product Portfolio

Table 40 Mylan N.V.: Key Developments

Table 41 Pfizer, Inc.: Overview

Table 42 Pfizer, Inc.: Product Portfolio

Table 43 Pfizer, Inc.: Key Developments

Table 44 Bayer Healthcare AG: Overview

Table 45 Bayer Healthcare AG: Product Portfolio

Table 46 Bayer Healthcare AG: Key Developments

Table 47 Boehringer Ingelheim: Overview

Table 48 Boehringer Ingelheim: Product Portfolio

Table 49 Boehringer Ingelheim: Key Developments

Table 50 Sanofi S.A.: Overview

Table 51 Sanofi S.A.: Product Portfolio

Table 52 Sanofi S.A.: Key Developments

Table 53 Abbott: Overview

Table 54 Abbott: Product Portfolio

Table 55 Abbott: Key Developments

Table 56 Aspen Holdings: Overview

Table 57 Aspen Holdings: Product Portfolio

Table 58 Aspen Holdings: Key Developments

Table 59 Bristol-Myers Squibb Company: Overview

Table 60 Bristol-Myers Squibb Company: Product Portfolio

Table 61 Bristol-Myers Squibb Company: Key Developments

그림 목록 (Figures)

List of Figures

Figure 01 Global Fondaparinux Market Share, By Type, 2022 & 2031 (%)

Figure 02 Global Fondaparinux Market Share, By Application, 2022 & 2031 (%)

Figure 03 Global Fondaparinux Market Share, By End User, 2022 & 2031 (%)

Figure 04 Global Fondaparinux Market Share, By Region, 2022 & 2031 (%)

Figure 05 Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 06 Global Fondaparinux Market Y-o-Y Growth, By Type, 2022-2031 (%)

Figure 07 Branded: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 08 Generic: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 09 Global Fondaparinux Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 10 Orthopedics: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 11 Cardiovascular: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 12 Others: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 13 Global Fondaparinux Market Y-o-Y Growth, By End User, 2022-2031 (%)

Figure 14 Hospitals and Clinics: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 15 Diagnostic Centers: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 16 Ambulatory Surgical Centers: Global Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 17 Global Fondaparinux Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 18 North America Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 19 North America Fondaparinux Market Share, By Type, 2022 & 2031 (%)

Figure 20 North America Fondaparinux Market Share, By Application, 2022 & 2031 (%)

Figure 21 North America Fondaparinux Market Share, By End User, 2022 & 2031 (%)

Figure 22 North America Fondaparinux Market Share, By Country, 2022 & 2031 (%)

Figure 23 South America Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 24 South America Fondaparinux Market Share, By Type, 2022 & 2031 (%)

Figure 25 South America Fondaparinux Market Share, By Application, 2022 & 2031 (%)

Figure 26 South America Fondaparinux Market Share, By End User, 2022 & 2031 (%)

Figure 27 South America Fondaparinux Market Share, By Country, 2022 & 2031 (%)

Figure 28 Europe Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 29 Europe Fondaparinux Market Share, By Type, 2022 & 2031 (%)

Figure 30 Europe Fondaparinux Market Share, By Application, 2022 & 2031 (%)

Figure 31 Europe Fondaparinux Market Share, By End User, 2022 & 2031 (%)

Figure 32 Europe Fondaparinux Market Share, By Country, 2022 & 2031 (%)

Figure 33 Asia-Pacific Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 34 Asia-Pacific Fondaparinux Market Share, By Type, 2022 & 2031 (%)

Figure 35 Asia-Pacific Fondaparinux Market Share, By Application, 2022 & 2031 (%)

Figure 36 Asia-Pacific Fondaparinux Market Share, By End User, 2022 & 2031 (%)

Figure 37 Asia-Pacific Fondaparinux Market Share, By Country, 2022 & 2031 (%)

Figure 38 Middle East & Africa Fondaparinux Market Value, 2022-2031 ($ Million)

Figure 39 Middle East & Africa Fondaparinux Market Share, By Type, 2022 & 2031 (%)

Figure 40 Middle East & Africa Fondaparinux Market Share, By Application, 2022 & 2031 (%)

Figure 41 Middle East & Africa Fondaparinux Market Share, By End User, 2022 & 2031 (%)

Figure 42 Dr. Reddy’s Laboratories, Inc.: Financials

Figure 43 GlaxoSmithKline Plc: Financials

Figure 44 Mylan N.V.: Financials

Figure 45 Pfizer, Inc.: Financials

Figure 46 Bayer Healthcare AG: Financials

Figure 47 Boehringer Ingelheim: Financials

Figure 48 Sanofi S.A.: Financials

Figure 49 Abbott: Financials

Figure 50 Aspen Holdings: Financials

Figure 51 Bristol-Myers Squibb Company: Financials

글로벌 Fondaparinux 시장(2023-2030년)

Global Fondaparinux Market - 2023-2030